Unión Europea - español - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - linaclotida - síndrome del intestino irritable - medicamentos para el estreñimiento - constella está indicado para el tratamiento sintomático del síndrome de colon irritable de moderado a intenso con estreñimiento (sii-e) en adultos.

Unión Europea - español - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ombitasvir, paritaprevir, ritonavir - hepatitis c, crónica - antivirales para uso sistémico - viekirax está indicado en combinación con otros medicamentos para el tratamiento de la hepatitis c crónica (chc) en adultos. para el virus de la hepatitis c (vhc) de genotipo específico de la actividad.

Unión Europea - español - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - atogepant - trastornos de la migraña - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Unión Europea - español - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leucemia, linfocítica, crónica, b-cell - agentes antineoplásicos - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

abbvie deutschland gmbh & co. kg alemania - cada jeringa prellenada contiene: risankizumab 150mg/ml - solucion inyectable - cada jeringa prellenada contiene: risankizumab 150mg/ml

Unión Europea - español - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - lopinavir, ritonavir - infecciones por vih - antivirals for systemic use, protease inhibitors - kaletra está indicado en combinación con otros medicamentos antirretrovirales para el tratamiento de adultos, adolescentes y niños infectados con el virus de la inmunodeficiencia humana (vih-1) a partir de los 14 días de edad. la elección de kaletra para tratar el inhibidor de la proteasa experimentado el vih-1 en pacientes infectados deben ser basados en las distintas pruebas de resistencia viral y la historia del tratamiento de los pacientes.

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

abbvie deutschland gmbh & co. kg alemania - cada jeringa prellenada contiene: risankizumab 75 mg/0.83 ml - solucion inyectable - cada jeringa prellenada contiene: risankizumab 75 mg/0.83 ml

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

abbvie deutschland gmbh & co. kg alemania - cantidad por cada comprimido upadacitinib hemihidrato 30.7 mg a a. correspondiente a 30 mg de upadacitinib en base anhidra - comprimido recubierto con pelicula de liberacion prolongada - cantidad por cada comprimido upadacitinib hemihidrato 30.7 mg a a. correspondiente a 30 mg de upadacitinib en base anhidra

Unión Europea - español - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoide - inmunosupresores - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

abbvie deutschland gmbh & co. kg alemania - cantidad por tableta: upadacitinib hemihidratado 46.1 a a. corresponde a 45 mg de upadacitinib base anhidra. - tableta recubierta de liberacion prolongada - cantidad por tableta: upadacitinib hemihidratado 46.1 a a. corresponde a 45 mg de upadacitinib base anhidra.